These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38648034)
1. Assessment of Mammalian Target of Rapamycin Pathway Activation in Basal Cell Carcinoma as a New Therapeutic Approach. Chang ALS; Brown R; Li S; Betancourt N; Teng J Am J Dermatopathol; 2024 Sep; 46(9):588-592. PubMed ID: 38648034 [TBL] [Abstract][Full Text] [Related]
3. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients. Karayannopoulou G; Euvrard S; Kanitakis J Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300 [TBL] [Abstract][Full Text] [Related]
4. SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas. Kim AL; Back JH; Chaudhary SC; Zhu Y; Athar M; Bickers DR J Invest Dermatol; 2018 Aug; 138(8):1716-1725. PubMed ID: 29550418 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608 [TBL] [Abstract][Full Text] [Related]
6. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin. Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603 [TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512 [TBL] [Abstract][Full Text] [Related]
8. AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome. Kim AL; Back JH; Zhu Y; Tang X; Yardley NP; Kim KJ; Athar M; Bickers DR Cancer Prev Res (Phila); 2016 Oct; 9(10):794-802. PubMed ID: 27388747 [TBL] [Abstract][Full Text] [Related]
10. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153 [TBL] [Abstract][Full Text] [Related]
11. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899 [TBL] [Abstract][Full Text] [Related]
12. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Dickinson SE; Janda J; Criswell J; Blohm-Mangone K; Olson ER; Liu Z; Barber C; Petricoin EF; Calvert VS; Einspahr J; Dickinson JE; Stratton SP; Curiel-Lewandrowski C; Saboda K; Hu C; Bode AM; Dong Z; Alberts DS; Timothy Bowden G Cancer Prev Res (Phila); 2016 Mar; 9(3):215-24. PubMed ID: 26801880 [TBL] [Abstract][Full Text] [Related]
14. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015 [TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048 [TBL] [Abstract][Full Text] [Related]
16. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. Tang JY; Chiou AS; Mackay-Wiggan JM; Aszterbaum M; Chanana AM; Lee W; Lindgren JA; Raphael MA; Thompson BJ; Bickers DR; Epstein EH Cancer Prev Res (Phila); 2014 Mar; 7(3):292-9. PubMed ID: 24441673 [TBL] [Abstract][Full Text] [Related]
17. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097 [TBL] [Abstract][Full Text] [Related]
18. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of the mechanistic target of rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma. Brinkhuizen T; Weijzen CA; Eben J; Thissen MR; van Marion AM; Lohman BG; Winnepenninckx VJ; Nelemans PJ; van Steensel MA PLoS One; 2014; 9(9):e106427. PubMed ID: 25181405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]